A
SAGE

AlphaQuest’s Sage Therapeutics SAGE Stock Holding History

AlphaQuest’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,003
Closed -$155K – 2275
2025
Q2 		$155K Buy
17,003
+12,972
+322% +$95.4K 0.02% 1266
2025
Q1 		$32K Buy
+4,031
New +$29.5K ﹤0.01% 1628
2024
Q4 		– Sell
-18,381
Closed -$133K – 1974
2024
Q3 		$133K Buy
18,381
+6,618
+56% +$60.6K 0.01% 1213
2024
Q2 		$128K Buy
11,763
+1,486
+14% +$19K 0.02% 873
2024
Q1 		$193K Sell
10,277
-1,745
-15% -$40.3K 0.03% 652
2023
Q4 		$261K Buy
+12,022
New +$238K 0.06% 562

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AlphaQuest's SAGE Position: Q3 2025 in Review

AlphaQuest sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 17,003 shares — an estimated $155K sold.

AlphaQuest first reported a position in SAGE in Q4 2023 and held it in 6 quarters. The position peaked at $261K in Q4 2023. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • AlphaQuest reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AlphaQuest sold 17,003 Sage Therapeutics shares in Q3 2025, an estimated $155K.
  • AlphaQuest first reported a position in Sage Therapeutics in Q4 2023 and held it in 6 quarters.
  • AlphaQuest's Sage Therapeutics position peaked at $261K in Q4 2023.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on AlphaQuest's 13F filing for Q3 2025, filed 3 Nov 2025.